Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
budoprutug (TNT119) / Climb Bio
NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)	Terminated	2	1	US	VB119	Tenet Medicines	Minimal Change Disease, Focal Segmental Glomerulosclerosis	05/23	10/23
NCT04652570: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy	Active, not recruiting	1/2	6	US	VB119	Tenet Medicines	Membranous Nephropathy	11/23	08/24
NCT06570434: Phase 1b/2a in SLE With Budoputug	Withdrawn	1/2	40	NA	budoprutug	Tenet Medicines	Systemic Lupus Erythematosus, SLE, B Cells	12/26	04/27
NCT07043946: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)	Recruiting	1/2	24	RoW	Budoprutug, TNT119	Climb Bio, Inc.	Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19	08/27	08/28
NCT07011043: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)	Recruiting	1	30	US, RoW	Budoprutug, TNT119	Climb Bio, Inc.	Systemic Lupus Erythematosus	04/27	04/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
budoprutug (TNT119) / Climb Bio
NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)	Terminated	2	1	US	VB119	Tenet Medicines	Minimal Change Disease, Focal Segmental Glomerulosclerosis	05/23	10/23
NCT04652570: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy	Active, not recruiting	1/2	6	US	VB119	Tenet Medicines	Membranous Nephropathy	11/23	08/24
NCT06570434: Phase 1b/2a in SLE With Budoputug	Withdrawn	1/2	40	NA	budoprutug	Tenet Medicines	Systemic Lupus Erythematosus, SLE, B Cells	12/26	04/27
NCT07043946: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)	Recruiting	1/2	24	RoW	Budoprutug, TNT119	Climb Bio, Inc.	Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19	08/27	08/28
NCT07011043: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)	Recruiting	1	30	US, RoW	Budoprutug, TNT119	Climb Bio, Inc.	Systemic Lupus Erythematosus	04/27	04/27